# New recurrence clinical trials, last 30 days: 26 (2026)

Updated November 19, 2026.

26 new trials for recurrence were first posted on ClinicalTrials.gov in the 30 days from October 20, 2026 to November 18, 2026, as read on November 19, 2026.

## The full list

New recurrence clinical trials, last 30 days: 26 rows for $5, first posted from October 20, 2026 to November 18, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/new/recurrence

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 22
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947043 | Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection | Tongji Hospital | Phase 1 | Recruiting | Recurrent or Metastatic Lung Cancer or Cervical Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947043) |
| November 18, 2026 | NCT07946393 | Preoperative CA 19-9 and the Pattern and Timing of Recurrence After Pancreatoduodenectomy (Whipple Operation) for Pancreatic Cancer | Minia University | Observational | Not yet recruiting | Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946393) |
| November 16, 2026 | NCT07939971 | A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML | TuHURA Biosciences, Inc. | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939971) |
| November 16, 2026 | NCT07937410 | Chronic Subdural Hematoma Recurrence | Carilion Clinic | Phase 1/2 | Recruiting | Chronic Subdural Hematoma, Recurrent | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937410) |
| November 13, 2026 | NCT07936266 | Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R... | Sponsor not shown (see the record) | Phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936266) |
| November 12, 2026 | NCT07934316 | LIMA1 Immunohistochemistry and Depth of Invasion as Prognostic Biomarkers in Oral Squamous Cell Carcinoma | Turku University Hospital | Observational | Enrolling by invitation | Oral Squamous Cell Carcinoma (OSCC), OSCC | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934316) |
| November 12, 2026 | NCT07933432 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Relapsed or Refractory Multiple Myeloma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933432) |
| November 12, 2026 | NCT07932496 | A Modular, Phase I/II Study to Evaluate CT204V-CD19 x CD20 in Participants With Relapsed or Refractory B-Cell Malignancies. | AstraZeneca | Phase 1/2 | Not yet recruiting | Relapsed or Refractory B-Cell Malignancies | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932496) |
| November 10, 2026 | NCT07929909 | A Phase I Clinical Study of YN003 in the Treatment of Glioma | Beijing Inno Medicine Co., Ltd. | Phase 1 | Recruiting | Glioma, Glioblastoma, Brain Neoplasms | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929909) |
| November 10, 2026 | NCT07929740 | Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS | Kura Oncology, Inc. | Phase 1 | Not yet recruiting | Myelodysplastic Syndrome (MDS)/AML, Myeloid Leukemia, Acute | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929740) |
| November 10, 2026 | NCT07927842 | BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Multiple Myeloma; Relapsed/Refractory Multiple Myeloma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927842) |
| November 9, 2026 | NCT07926464 | Laparoscopic Transabdominal Preperitoneal Technique in Repair of Recurrent Inguinal Hernia | Port Said University hospital | Not applicable | Completed | Laparoscopic, Transabdominal Preperitoneal, Repair, Recurrent, Inguinal Hernia | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926464) |
| November 6, 2026 | NCT07923071 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment | Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923071) |
| November 6, 2026 | NCT07920796 | Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute Leukemia | Guangdong Second Provincial General Hospital | Phase 2 | Enrolling by invitation | Acute Leukemia, High Risk, Acute Leukemia Refractory, Acute Leukemia, Relapsed | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920796) |
| November 3, 2026 | NCT07913594 | Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma | Olivia Newton-John Cancer Research Institute | Phase 2 | Not yet recruiting | Peripheral T-Cell Lymphoma Refractory | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913594) |
| November 2, 2026 | NCT07910708 | GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia | Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital | Phase 1 | Recruiting | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910708) |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| October 29, 2026 | NCT07905664 | Better Care Closer to Home: Enhancing Primary and Community Care | Universidad Complutense de Madrid | Not applicable | Not yet recruiting | Diabetic Foot Disease, Recurrence | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905664) |
| October 28, 2026 | NCT07901803 | Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma | Washington University School of Medicine | Phase 2 | Not yet recruiting | Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901803) |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 27, 2026 | NCT07898436 | Menin Inhibitors in Pediatric Relapsed or Refractory Acute Leukemia | University Hospital, Strasbourg, France | Observational | Recruiting | Acute Leukemia, Relapsed or Refractory Pediatric Leukemia, KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898436) |
| October 27, 2026 | NCT07897136 | CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897136) |
| October 26, 2026 | NCT07896278 | Onlay vs. Sublay Mesh Hernioplasty for Primary Ventral Hernia | Provincial Headquarter Teaching Hospital Gilgit | Not applicable | Completed | Ventral Hernia Repair, Hernia Abdominal Wall | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896278) |
| October 22, 2026 | NCT07890025 | CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study | Hospital Universitario Dr. Jose E. Gonzalez | Phase 1/2 | Not yet recruiting | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890025) |
| October 20, 2026 | NCT07883941 | Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883941) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 9 |
| Phase 1/2 | 6 |
| Phase 2 | 4 |
| Phase 3 | 1 |
| Not applicable | 3 |
| Observational | 3 |

## Sponsors posting most

| Sponsor | Trials |
| --- | --- |
| Tongji Hospital | 1 |
| Minia University | 1 |
| TuHURA Biosciences, Inc. | 1 |
| Carilion Clinic | 1 |
| Turku University Hospital | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Beijing Inno Medicine Co., Ltd. | 1 |
| Kura Oncology, Inc. | 1 |
| Port Said University hospital | 1 |
| [Syndax Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/syndax-pharmaceuticals) | 1 |
| Guangdong Second Provincial General Hospital | 1 |
| Olivia Newton-John Cancer Research Institute | 1 |
| Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital | 1 |
| Crescent Biopharma, Inc. | 1 |
| Universidad Complutense de Madrid | 1 |
| Washington University School of Medicine | 1 |
| Medsyn Biopharma, LLC | 1 |
| University Hospital, Strasbourg, France | 1 |
| Provincial Headquarter Teaching Hospital Gilgit | 1 |
| Hospital Universitario Dr. Jose E. Gonzalez | 1 |
| National Research Center for Hematology, Russia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B mining companies in the United States](https://specstream.ai/data/businesses/b2b-mining-companies/united-states)
- [Steel fabricators in the United States](https://specstream.ai/data/businesses/steel-fabricators/united-states)
- [Occupational medicine clinics in the United States](https://specstream.ai/data/businesses/occupational-medicine-clinics/united-states)
- [Glass manufacturers in the United States](https://specstream.ai/data/businesses/glass-manufacturers/united-states)
- [Civil engineering firms in the United States](https://specstream.ai/data/businesses/civil-engineering-firms/united-states)
- [Wine bars in the United States](https://specstream.ai/data/businesses/wine-bars/united-states)
